

CME/CE Post Test

Record your answers to these questions on the answer sheet on page 24.

- 1. For patients undergoing stem-cell transplantation and high-dose chemotherapy or total-body irradiation, mucositis occurs at a frequency of:**
 - a. 10%–20%
 - b. 25%–40%
 - c. 60%
 - d. 50%–100%
- 2. In a study of patients with solid tumors who experienced chemotherapy-related myelosuppression, the presence of mucositis was associated with increased:**
 - a. Weight loss
 - b. Chemotherapy dose reductions
 - c. Infection rate and antibiotic use
 - d. All of the above
- 3. Common conditions that can mimic the appearance of oral mucositis and should be considered in a differential diagnosis include:**
 - a. Herpes simplex virus
 - b. Oral candidiasis
 - c. Graft-versus-host disease
 - d. All of the above
- 4. Updated treatment guidelines for management of oral mucositis recommend:**
 - a. Use of alcohol-based mouthwashes to alleviate or prevent symptoms
 - b. Regular assessment and routine oral care
 - c. Postponement of planned oral surgery
 - d. Avoidance of topical anesthetics
- 5. Palifermin is best described as a:**
 - a. Epidermal growth factor receptor (EGFR) inhibitor
 - b. Keratinocyte growth factor-1
 - c. Fibroblast growth factor
 - d. Angiogenic factor
- 6. A phase III trial of _____ demonstrated a reduced incidence of oral mucositis in breast cancer patients treated with chemotherapy, with a suggestion of a carryover effect after crossover to placebo.**
 - a. Palifermin
 - b. IL-11
 - c. N-acetylcysteine
 - d. AES-14
- 7. Chemotherapy with a high degree of emetogenic risk indicates that without effective prophylaxis, emesis may occur at an incidence of:**
 - a. 45%
 - b. $\geq 60\%$
 - c. $< 75\%$
 - d. $> 90\%$
- 8. The foundation of antiemetic therapy has been largely based on use of:**
 - a. 5-HT₃ receptor antagonists
 - b. Antidopaminergic agents
 - c. Aprepitant
 - d. Corticosteroids only
- 9. Delayed chemotherapy-induced nausea and vomiting (CINV) occurs after the first 24 hours and up to ____ hours following administration of chemotherapy.**
 - a. 48
 - b. 72
 - c. 96
 - d. 120
- 10. Palonosetron is distinct from other 5-HT₃ receptor antagonists due in part to a 100-fold greater:**
 - a. Absorption
 - b. Intracellular uptake
 - c. Binding affinity for type-3 serotonin receptor
 - d. Inhibition of NK-1 receptor
- 11. In a retrospective study of oncology practices, what percentage of physicians and nurses underestimated the incidence of delayed CINV by approximately 30%?**
 - a. 15%
 - b. $< 30\%$
 - c. 55%
 - d. $> 75\%$
- 12. ASCO treatment guidelines for antiemetic therapy recommend that prior to treatment with highly emetogenic chemotherapy patients should receive:**
 - a. 5-HT₃ receptor antagonist only
 - b. 5-HT₃ receptor antagonist and dexamethasone
 - c. 5-HT₃ receptor antagonist, dexamethasone, and aprepitant
 - d. Palonosetron

CME/CE Answer Sheet and Evaluation

The Impact of Treatment Side Effects on the Patient: Chemotherapy-Induced Nausea and Vomiting and Mucositis
Journal of Supportive Oncology, Vol. 5, No. 2, Supp. 1

This issue of *The Journal of Supportive Oncology* provides 1 **free AMA PRA Category 1 Credit(s)**[™] and 0.75 **free** nursing CE contact hours.

To receive CME credit/CE contact hours for this educational activity, study the information presented in this supplement before answering each post-test question (see page 23) on the answer sheet below and complete the evaluation form. Post tests without a complete name and mailing address cannot be processed for CME credit or CE contact hours.

Mail a photocopy of the completed answer sheet and evaluation form by **February 15, 2008**, to:

Elsevier Office of Continuing Medical Education • Department 910188
685 Route 202/206 • Bridgewater, NJ 08807

CME/CE Post-Test Answer Sheet

Circle the single most appropriate answer for each question on the preceding page.

1.	A	B	C	D	5.	A	B	C	D	9.	A	B	C	D
2.	A	B	C	D	6.	A	B	C	D	10.	A	B	C	D
3.	A	B	C	D	7.	A	B	C	D	11.	A	B	C	D
4.	A	B	C	D	8.	A	B	C	D	12.	A	B	C	D

Overall Evaluation

Did you achieve the CME/CE stated educational objectives? Yes No

If no, which objectives were not met? _____

Were the purpose and objectives consistent with the content? Yes No

If not, how were they inconsistent? _____

Was this supplement effective as a teaching method for you? Yes No

If not, why not? _____

Will the content of this supplement be useful in your physician/nursing role? Yes No

If yes, give at least one example how: _____

Did you find the information presented to be objective, fair, balanced, and free of commercial bias? Yes No

Comment: _____

Please indicate the amount of time (in hours and minutes) you spent on this educational activity: _____

PLEASE PRINT

Name (first, last)		Degree
Specialty		
Mailing address		
City	State	ZIP code
E-mail address		
Telephone (with area code)	Fax (with area code)	
Signature	Date	